Signaling Pathways as Therapeutic Targets for Cancer

Dear Colleagues,

The hallmarks of cancer, based on Weinberg and Hannahan’s original classification, currently include several features such as activating invasion and metastasis, genome instability and mutation, resisting cell death, deregulating cellular metabolism, and sustaining proliferative signaling, among others. In all of these processes, cell signal transduction is fundamental. It has been largely known that signaling pathways are deregulated in many tumors and thus have been targeted in antitumor therapies. Key signaling pathways that are altered in cancer cells are the Wnt/β-Catenin pathway, the PIK3/AKT/mTOR pathway, the MAPK pathway, the NOTCH pathway, and the NF-kB pathway. In addition to these, other important signaling pathways involved include, but are not limited to, the p53 signaling pathway, the TGF-β pathway, the Hedgehog pathway, and pathways involved in cancer metabolism (e.g., glucose or fatty acid metabolism), epigenetic mechanisms, and immune responses. Signaling pathways in cancer are targeted via specific antibodies, small molecules (e.g., kinase inhibitors), or genetic approaches. Therapies include the use of single or combinatorial approaches, but resistance and toxicity are some of the challenges that remain to be solved. This Special Issue will focus on novel therapeutic approaches to target signaling pathways in cancer, with emphasis on recent discoveries, combinatorial approaches, new targets, and promising new drugs.

Dr. Fabian Benencia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.